Arca
Skip to content
Tools
Tools

Rifampin

ANDA 204101, held by Avet Lifesciences. Rifampin.

  • First approved: Aug 18, 2014
  • Supplements approved: 7
  • Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 8 submissions below
DateSubmissionStatusDocuments
Aug 18, 2014Original applicationApprovedNone posted

Products

1 strengths and forms
ProductActive ingredientMarketing
Rifampin600MG/VIAL · injectable;injectionRifampinDiscontinued
All 8 submissions, including labeling and manufacturing supplements
DateSubmissionStatusDocuments
Apr 2, 2024Supplement 12Labeling · Standard reviewApprovedNone posted
Apr 2, 2024Supplement 11Labeling · Standard reviewApprovedNone posted
Oct 26, 2021Supplement 10Labeling · Standard reviewApprovedNone posted
Aug 25, 2020Supplement 9Labeling · Standard reviewApprovedNone posted
Feb 11, 2020Supplement 8Labeling · Standard reviewApprovedNone posted
Feb 11, 2020Supplement 7Labeling · Standard reviewApprovedNone posted
Feb 11, 2020Supplement 6Labeling · Standard reviewApprovedNone posted
Aug 18, 2014Original applicationApprovedNone posted

Identifiers

Application
ANDA 204101

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.